Triarico Silvia, Rivetti Serena, Capozza Michele Antonio, Romano Alberto, Maurizi Palma, Mastrangelo Stefano, Attinà Giorgio, Ruggiero Antonio
UOSD di Oncologia Pediatrica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy.
Scuola di Specializzazione in Pediatria, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy.
Cancers (Basel). 2022 Jun 24;14(13):3103. doi: 10.3390/cancers14133103.
The incidence of PAC is relatively infrequent among pregnant women. However, it has gradually increased in recent years, becoming a challenging area for clinicians that should take into account in the same way maternal benefits and fetal potential risks correlated to the antineoplastic treatment. None of the antineoplastic drugs is completely risk-free during the pregnancy, the timing of exposure and transplacental transfer properties influence the toxicity of the fetus. Despite the lack of guidelines about the management of PAC, several studies have described the use and the potential fetal and neonatal adverse events of antineoplastic drugs during pregnancy. We provide a review of the available literature about the transplacental passage and fetal effects of chemotherapy and targeted agents, to guide the clinicians in the most appropriate choices for the management of PAC.
妊娠滋养细胞疾病（PAC）在孕妇中的发病率相对较低。然而，近年来其发病率逐渐上升，这对临床医生来说是一个具有挑战性的领域，临床医生在考虑抗肿瘤治疗对母体的益处和对胎儿的潜在风险时应予以同等重视。在孕期，没有一种抗肿瘤药物是完全无风险的，接触药物的时间和经胎盘转运特性会影响胎儿的毒性。尽管缺乏关于PAC管理的指南，但多项研究描述了孕期使用抗肿瘤药物及其对胎儿和新生儿的潜在不良事件。我们对现有关于化疗药物和靶向药物经胎盘转运及对胎儿影响的文献进行综述，以指导临床医生在PAC管理中做出最合适的选择。
